A new study published in the journal Cephalalgia found that atogepant, a preventive treatment for migraines, significantly improves quality of life and functioning among patients with different types of migraine. Researchers analyzed data from three trials: ADVANCE, PROGRESS, and ELEVATE.
The study focused on three measures of migraine-related quality of life: Migraine-Specific Quality of Life questionnaire version 2.1 (MSQv2.1), Headache Impact Test-6 (HIT-6), and Activity Impairment in Migraine–Diary (AIM-D). The results showed that patients taking atogepant experienced greater improvements in these measures compared to those taking a placebo.
The study found significant benefits for low-frequency episodic migraine, high-frequency episodic migraine, and chronic migraine. Patients who received atogepant had better changes from baseline to week 12 in the MSQv2.1 Role Function-Restrictive domain scores, HIT-6 total scores, and AIM-D diary entries.
According to the authors, these results demonstrate the value of preventive treatment with atogepant for reducing migraine-attributed impacts on daily life, health, and well-being across different patient populations.
Source: https://www.patientcareonline.com/view/atogepant-improves-qol-in-chronic-episodic-migraine-daily-dose